Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $21.59, for a total value of $70,167.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at $280,670. The trade was a 20.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total value of $130,672.50.

Enliven Therapeutics Stock Up 2.0 %

ELVN stock opened at $21.27 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03. The company has a market cap of $1.04 billion, a PE ratio of -11.19 and a beta of 1.04. The business’s 50-day simple moving average is $23.18 and its 200 day simple moving average is $24.31.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several research analyst reports. BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Robert W. Baird raised their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $38.25.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. American Century Companies Inc. lifted its stake in Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares during the period. Marshall Wace LLP bought a new position in Enliven Therapeutics during the second quarter worth about $4,489,000. The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics during the second quarter worth about $322,000. SG Americas Securities LLC bought a new position in Enliven Therapeutics during the third quarter worth about $256,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.